MGD024
CD123+ Hematologic Malignancies
Phase 1Active
Key Facts
About MacroGenics
MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop life-changing medicines for patients with cancer. The company has built a broad pipeline of investigational product candidates, including its lead bispecific DART® molecule lorigerlimab, and has established strategic collaborations with global pharmaceutical companies. With in-house GMP manufacturing capabilities and a focus on innovative antibody engineering, MacroGenics aims to address significant unmet needs in oncology.
View full company profile